Gaithersburg, MD—February 14, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of Christopher M. Jewell, PhD/MS as Chief Scientific Officer. Dr. Jewell’s predecessor, Michael Singer, MD, PhD, has been named Chairman of the Board and Chief Strategy Officer.
Dr. Jewell is a leader in the immune engineering and nanotechnology fields. Over the past decade at the University of Maryland as the MPower Professor and Minta Martin Professor, he secured over $25M in funding and published 125 manuscripts and patents, including papers in Nature, Nature Biotechnology, Nature Materials, and others. Dr. Jewell has received over 50 awards, including the Presidential Early Career Award for Scientists and Engineers (PECASE) – the nation’s highest honor for such scientists. He is also an elected fellow of numerous professional societies. Dr. Jewell’s translational medicine skills benefit from his experience at Boston Consulting Group and as an advisor to dozens of drugmakers over the past 15 years.
“I am delighted that Chris will lead our growing team of scientists at Cartesian,” said Murat Kalayoglu, MD, PhD, President and CEO at Cartesian. “Chris’s sterling record of discovery, invention, and scholarship will accelerate our current path, and open new ones, to deliver transformative RNA cell therapies to patients.”
About Cartesian Therapeutics
Cartesian is pioneering RNA cell therapies for autoimmune diseases and cancer. The company’s lead asset, Descartes-08, is a first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. For more information visit www.cartesiantherapeutics.com.
Media queries: Annette Larkin, annette@renewpr.com or m: 703.772.6427
